stanozolol has been researched along with Diabetes Mellitus, Type 2 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kluft, C; Lowe, GD; MacCuish, AC; Small, M | 1 |
Forbes, CD; MacCuish, AC; Small, M | 1 |
Forbes, CD; Lowe, GD; MacCuish, AC; Small, M | 1 |
3 other study(ies) available for stanozolol and Diabetes Mellitus, Type 2
Article | Year |
---|---|
Tissue plasminogen activator inhibition in diabetes mellitus.
Topics: Antibodies, Monoclonal; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Kinetics; Male; Middle Aged; Plasminogen Inactivators; Stanozolol; Tissue Plasminogen Activator | 1989 |
Metabolic effects of stanozolol in type II diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Stanozolol; Triglycerides | 1986 |
The effects of oral stanozolol on fibrinolysis in type 2 diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; alpha-2-Antiplasmin; Diabetes Mellitus, Type 2; Fibrinogen; Fibrinolysis; Humans; Middle Aged; Plasminogen; Research Design; Stanozolol | 1986 |